Our study found three key results. First, the new vaccine produced antibodies in 90% of patients, showing it is effective at triggering an immune response. Second, no serious safety issues were reported. Finally, side effects were mild, with fatigue being most commonly reported. The vaccine shows promise as safe and able to produce an immune response, warranting further study.